東京大学 · Biochemistry, Genetics and Molecular Biology
호라시오 카브랄 교수의 연구실은 나노의학 분야에서 암 치료의 정밀성과 효능을 극대화하기 위한 스마트 나노캐리어 개발에 주력하고 있습니다. 특히, 종양 미세환경을 정상화시키는 약물(예: 덱사메타존)과의 조합, 면역요법의 효과를 극대화할 수 있는 스파티오타임스피컬 제어 기반 나노의약품 설계, 그리고 임상 적용에 유리한 비바이러스형 나노시스템 개발이 핵심 연구 방향입니다. 다양한 암 모델(특히 췌열선암 등 임상적으로 어려운 암)에서의 나노캐리어의 체내 분포와 치료 효과를 실시간으로 평가하는 고급 생체영상 기반 연구도 진행 중입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The increasing importance of nanotechnology in the biomedical field and the recent progress of nanomedicines into clinical testing have spurred the development of even more sophisticated nanoscale drug carriers. Current nanocarriers can successfully target cells, release their cargo in response to stimuli, and selectively deliver drugs. More sophisticated nanoscale carriers should evolve into fully integrated vehicles with more complex capabilities. First, they should be able to sense targets in
Messenger RNA (mRNA)-based therapies offer great promise for the treatment of a variety of diseases. In 2020, two FDA approvals of mRNA-based vaccines have elevated mRNA vaccines to global recognition. However, the therapeutic capabilities of mRNA extend far beyond vaccines against infectious diseases. They hold potential for cancer vaccines, protein replacement therapies, gene editing therapies, and immunotherapies. For realizing such advanced therapies, it is crucial to develop effective carri
Occult nodal metastases increase the risk of cancer recurrence, demoting prognosis and quality of life of patients. While targeted drug delivery by using systemically administered nanocarriers can potentially control metastatic disease, lymph node metastases have been mainly dealt by locally injecting nanocarriers, which may not always be applicable. Herein, we demonstrated that sub-50 nm polymeric micelles incorporating platinum anticancer drugs could target lymph node metastases in a syngeneic
Dexamethasone is a glucocorticoid steroid with anti-inflammatory properties used to treat many diseases, including cancer, in which it helps manage various side effects of chemo-, radio-, and immunotherapies. Here, we investigate the tumor microenvironment (TME)-normalizing effects of dexamethasone in metastatic murine breast cancer (BC). Dexamethasone normalizes vessels and the extracellular matrix, thereby reducing interstitial fluid pressure, tissue stiffness, and solid stress. In turn, the p
Therapeutic manipulation of the immune system against cancer has revolutionized the treatment of several advanced-stage tumors. While many have benefited from these treatments, the proportion of patients responding to immunotherapies is still low. Nanomedicines have promise to revolutionize tumor treatments through spatiotemporal control of drug activity. Such control of drug function could allow enhanced therapeutic actions of immunotherapies and reduced side effects. However, only a handful of
Nanoscaled drug-loaded carriers are of particular interest for efficient tumor therapy as numerous studies have shown improved targeting and efficacy. Nevertheless, most of these studies have been performed against allograft and xenograft tumor models, which have altered microenvironment features affecting the accumulation and penetration of nanocarriers. Conversely, the evaluation of nanocarriers on genetically engineered mice, which can gradually develop clinically relevant tumors, permits the
